Epigenetic mechanisms regulating neural development and pediatric brain tumor formation: A review

Journal of Neurosurgery: Pediatrics

Volumn 8, Issue 2, 2011, Pages 119-132

  Faria, Claudia M C ^a,b   Rutka, James T ^a   Smith, Christian ^a   Kongkham, Paul ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Embryonic development; Epigenetic regulation; Neural development; Oncology; Pediatric brain tumor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; RNA; ROMIDEPSIN; TEMOZOLOMIDE; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURGERY; CELL CYCLE ARREST; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; DRUG POTENTIATION; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; EPENDYMOMA; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GLIOBLASTOMA; GLIOMA; HISTONE METHYLATION; HISTONE MODIFICATION; HOX GENE; HUMAN; MEDULLOBLASTOMA; MYELODYSPLASTIC SYNDROME; NERVE CELL DIFFERENTIATION; NEUROECTODERM TUMOR; NONHUMAN; PRIMITIVE NEUROECTODERMAL TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROCESSING; REVIEW; RHABDOID TUMOR; TREATMENT RESPONSE;

BRAIN; BRAIN NEOPLASMS; CHILD; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL;

EID: 79961109818     PISSN: 19330707     EISSN: 19330715     Source Type: Journal    
DOI: 10.3171/2011.5.PEDS1140     Document Type: Review

References (158)

1. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P: Molecular Biology of the Cell, ed 5. New York: Garland Science, 2008
2. Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, de Campos JM, Gutierrez M, et al: Aberrant CpG island methylation of multiple genes in ependymal tumors. J Neurooncol 67:159-165, 2004 (Pubitemid 38418264)
3. Anderton JA, Lindsey JC, Lusher ME, Gilbertson RJ, Bailey S, Ellison DW, et al: Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro Oncol 10:981-994, 2008
4. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, et al: Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 101:946-958, 2009
5. Atkinson S, Armstrong L: Epigenetics in embryonic stem cells: regulation of pluripotency and differentiation. Cell Tissue Res 331:23-29, 2008 (Pubitemid 50003208)
6. Ballas N, Mandel G: The many faces of REST oversee epigenetic programming of neuronal genes. Curr Opin Neurobiol 15:500-506, 2005 (Pubitemid 41394393)
7. Barber BA, Rastegar M: Epigenetic control of Hox genes during neurogenesis, development, and disease. Ann Anat 192:261-274, 2010
8. Bassett A, Cooper S, Wu C, Travers A: The folding and unfolding of eukaryotic chromatin. Curr Opin Genet Dev 19:159-165, 2009
9. Berger SL: The complex language of chromatin regulation during transcription. Nature 447:407-412, 2007
10. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al: A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315-326, 2006
11. Binning MJ, Niazi T, Pedone CA, Lal B, Eberhart CG, Kim KJ, et al: Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth. Cancer Res 68:7838-7845, 2008
12. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 16:6-21, 2002
13. Bird A: Perceptions of epigenetics. Nature 447:396-398, 2007
14. Bonasio R, Tu S, Reinberg D: Molecular signals of epigenetic states. Science 330:612-616, 2010
15. Brena RM, Costello JF: Genome-epigenome interactions in cancer. Hum Mol Genet 16 Spec No 1:R96-R105, 2007
16. Breving K, Esquela-Kerscher A: The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 42:1316-1329, 2010
17. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, et al: Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 7:2727-2730, 2001 (Pubitemid 32911377)
18. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866, 2006 (Pubitemid 44629897)
19. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:15524-15529, 2002 (Pubitemid 35403967)
20. Carthew RW, Sontheimer EJ: Origins and mechanisms of miRNAs and siRNAs. Cell 136:642-655, 2009
21. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, et al: Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 27:385-389, 2009
22. Ciani L, Salinas PC: WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci 6:351-362, 2005 (Pubitemid 40593481)
23. Collins LJ, Chen XS: Ancestral RNA: the RNA biology of the eukaryotic ancestor. RNA Biol 6:495-502, 2009
24. Conaco C, Otto S, Han JJ, Mandel G: Reciprocal actions of REST and a microRNA promote neuronal identity. Proc Natl Acad Sci U S A 103:2422-2427, 2006 (Pubitemid 43271685)
25. Crawford JR, MacDonald TJ, Packer RJ: Medulloblastoma in childhood: new biological advances. Lancet Neurol 6:1073-1085, 2007 (Pubitemid 350116703)
26. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10:704-714, 2009
27. Davalos V, Esteller M: MicroRNAs and cancer epigenetics: a macrorevolution. Curr Opin Oncol 22:35-45, 2010
28. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-749, 2003 (Pubitemid 36399066)
29. De Smaele E, Ferretti E, Gulino A: MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res 1338:100-111, 2010
30. Delcuve GP, Rastegar M, Davie JR: Epigenetic control. J Cell Physiol 219:243-250, 2009
31. Di Leva G, Croce CM: Roles of small RNAs in tumor formation. Trends Mol Med 16:257-267, 2010
32. Diede SJ, Guenthoer J, Geng LN, Mahoney SE, Marotta M, Olson JM, et al: DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proc Natl Acad Sci U S A 107:234-239, 2010
33. Dubuc AM, Northcott PA, Mack S, Witt H, Pfister S, Taylor MD: The genetics of pediatric brain tumors. Curr Neurol Neurosci Rep 10:215-223, 2010
34. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286-298, 2007
35. Esteller M: Epigenetics in cancer. N Engl J Med 358:1148-1159, 2008
36. Everhard S, Kaloshi G, Crinière E, Benouaich-Amiel A, Lejeune J, Marie Y, et al: MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740-743, 2006 (Pubitemid 46048490)
37. Fabbri M, Calin GA: Epigenetics and miRNAs in human cancer. Adv Genet 70:87-99, 2010
38. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, et al: Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 64:7787-7793, 2004 (Pubitemid 39446911)
39. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89-92, 1983 (Pubitemid 13154475)
40. Fernandez-L A, Northcott PA, Taylor MD, Kenney AM: Normal and oncogenic roles for microRNAs in the developing brain. Cell Cycle 8:4049-4054, 2009
41. Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M, et al: Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J 27:2616-2627, 2008
42. Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, et al: MicroRNA profiling in human medulloblastoma. Int J Cancer 124:568-577, 2009
43. Finkelstein-Shechter T, Gassas A, Mabbott D, Huang A, Bartels U, Tabori U, et al: Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy. J Pediatr Hematol Oncol 32:e182-e186, 2010
44. Frühwald MC, O'Dorisio MS, Dai Z, Rush LJ, Krahe R, Smiraglia DJ, et al: Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Genes Chromosomes Cancer 30:38-47, 2001
45. Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A, Frühwald MC: Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120:1787-1794, 2007 (Pubitemid 46399367)
46. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, et al: Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052-2058, 2009
47. Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, et al: MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS ONE 4:e4998, 2009
48. Gilbertson RJ, Ellison DW: The origins of medulloblastoma subtypes. Annu Rev Pathol 3:341-365, 2008 (Pubitemid 351488285)
49. Godfraind C: Classification and controversies in pathology of ependymomas. Childs Nerv Syst 25:1185-1193, 2009
50. Goldberg AD, Allis CD, Bernstein E: Epigenetics: a landscape takes shape. Cell 128:635-638, 2007 (Pubitemid 46273578)
51. Grimm D: Small silencing RNAs: state-of-the-art. Adv Drug Deliv Rev 61:672-703, 2009
52. Guessous F, Li Y, Abounader R: Signaling pathways in medulloblastoma. J Cell Physiol 217:577-583, 2008
53. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85:841-851, 1996 (Pubitemid 26192135)
54. Hajkova P: Epigenetic reprogramming - taking a lesson from the embryo. Curr Opin Cell Biol 22:342-350, 2010
55. Hake SB, Allis CD: Histone H3 variants and their potential role in indexing mammalian genomes: the "H3 barcode hypothesis." Proc Natl Acad Sci U S A 103:6428-6435, 2006
56. Hamby ME, Coskun V, Sun YE: Transcriptional regulation of neuronal differentiation: the epigenetic layer of complexity. Biochim Biophys Acta 1779:432-437, 2008
57. Hamilton DW, Lusher ME, Lindsey JC, Ellison DW, Clifford SC: Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett 227:75-81, 2005 (Pubitemid 41033094)
58. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al: The molecular basis of Turcot's syndrome. N Engl J Med 332:839-847, 1995
59. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
60. Hervouet E, Vallette FM, Cartron PF: Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics 4:487-499, 2009
61. Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, et al: Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 30:978-989, 2011
62. Hirabayashi Y, Gotoh Y: Epigenetic control of neural precursor cell fate during development. Nat Rev Neurosci 11:377-388, 2010
63. Ieraci A, Forni PE, Ponzetto C: Viable hypomorphic signaling mutant of the Met receptor reveals a role for hepatocyte growth factor in postnatal cerebellar development. Proc Natl Acad Sci U S A 99:15200-15205, 2002 (Pubitemid 35334633)
64. Inda MM, Muñoz J, Coullin P, Fauvet D, Danglot G, Tuñón T, et al: High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma. Histopathology 48:579-587, 2006
65. Iorio MV, Piovan C, Croce CM: Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 1799:694-701, 2010
66. Jenuwein T, Allis CD: Translating the histone code. Science 293:1074-1080, 2001 (Pubitemid 32758077)
67. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128:683-692, 2007 (Pubitemid 46273572)
68. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57, 2007 (Pubitemid 46053042)
69. Kiefer JC: Epigenetics in development. Dev Dyn 236:1144-1156, 2007
70. Kim JK, Samaranayake M, Pradhan S: Epigenetic mechanisms in mammals. Cell Mol Life Sci 66:596-612, 2009
71. Klose RJ, Zhang Y: Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 8:307-318, 2007 (Pubitemid 46474659)
72. Kongkham PN, Northcott PA, Croul SE, Smith CA, Taylor MD, Rutka JT: The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene 29:3017-3024, 2010
73. Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, et al: An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res 68:9945-9953, 2008
74. Kongkham PN, Onvani S, Smith CA, Rutka JT: Inhibition of the MET receptor tyrosine kinase as a novel therapeutic strategy in medulloblastoma. Transl Oncol 3:336-343, 2010
75. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, et al: Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28:3182-3190, 2010
76. Kouzarides T: Chromatin modifications and their function. Cell 128:693-705, 2007
77. Kriegstein A, Alvarez-Buylla A: The glial nature of embryonic and adult neural stem cells. Annu Rev Neurosci 32:149-184, 2009
78. Kulis M, Esteller M: DNA methylation and cancer. Adv Genet 70:27-56, 2010
79. Kumar KS, Sonnemann J, Beck JF: Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells. Oncol Rep 16:1047-1052, 2006
80. Lane AA, Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459-5468, 2009
81. Lau P, Hudson LD: MicroRNAs in neural cell differentiation. Brain Res 1338:14-19, 2010
82. Lau P, Verrier JD, Nielsen JA, Johnson KR, Notterpek L, Hudson LD: Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J Neurosci 28:11720-11730, 2008
83. Li X, Jin P: Roles of small regulatory RNAs in determining neuronal identity. Nat Rev Neurosci 11:329-338, 2010
84. Li Y, Guessous F, Johnson EB, Eberhart CG, Li XN, Shu Q, et al: Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest 88:98-111, 2008 (Pubitemid 351161270)
85. Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, et al: The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 65:9355-9362, 2005 (Pubitemid 41508003)
86. Lindsey JC, Anderton JA, Lusher ME, Clifford SC: Epigenetic events in medulloblastoma development. Neurosurg Focus 19(5):E10, 2005
87. Lindsey JC, Lusher ME, Strathdee G, Brown R, Gilbertson RJ, Bailey S, et al: Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer 118:346-352, 2006 (Pubitemid 41779073)
88. Liu J, Casaccia P: Epigenetic regulation of oligodendrocyte identity. Trends Neurosci 33:193-201, 2010
89. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007 (Pubitemid 47103521)
90. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al: MicroRNA expression profiles classify human cancers. Nature 435:834-838, 2005 (Pubitemid 40839735)
91. Lu Y, Ryan SL, Elliott DJ, Bignell GR, Futreal PA, Ellison DW, et al: Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS ONE 4:e6159, 2009
92. MacDonald JL, Roskams AJ: Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation. Prog Neurobiol 88:170-183, 2009
93. MacDonald TJ: Aggressive infantile embryonal tumors. J Child Neurol 23:1195-1204, 2008
94. Mack SC, Taylor MD: The genetic and epigenetic basis of ependymoma. Childs Nerv Syst 25:1195-1201, 2009
95. Mattick JS, Amaral PP, Dinger ME, Mercer TR, Mehler MF: RNA regulation of epigenetic processes. Bioessays 31:51-59, 2009
96. Mehnert JM, Kelly WK: Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 13:23-29, 2007
97. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, et al: Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:766-770, 2008
98. Michalowski MB, de Fraipont F, Michelland S, Entz-Werle N, Grill J, Pasquier B, et al: Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet 166:74-81, 2006
99. Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P, et al: HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res 16:3240-3252, 2010
100. Miranda TB, Jones PA: DNA methylation: the nuts and bolts of repression. J Cell Physiol 213:384-390, 2007 (Pubitemid 47509717)
101. Moazed D: Small RNAs in transcriptional gene silencing and genome defence. Nature 457:413-420, 2009
102. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, et al: Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 24:5223-5233, 2006 (Pubitemid 46631366)
103. Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, et al: Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 30:755-766, 2008
104. Moore SW: Developmental genes and cancer in children. Pediatr Blood Cancer 52:755-760, 2009
105. Mühlisch J, Schwering A, Grotzer M, Vince GH, Roggendorf W, Hagemann C, et al: Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene 25:1111-1117, 2006 (Pubitemid 43277018)
106. Nagarajan RP, Costello JF: Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol 19:188-197, 2009
107. Nakahara Y, Northcott PA, Li M, Kongkham PN, Smith C, Yan H, et al: Genetic and epigenetic inactivation of Kruppellike factor 4 in medulloblastoma. Neoplasia 12:20-27, 2010
108. Northcott PA, Fernandez-L A, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, et al: The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69:3249-3255, 2009
109. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408-1414, 2011
110. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, et al: Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41:465-472, 2009
111. Okano M, Bell DW, Haber DA, Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247-257, 1999 (Pubitemid 29519904)
112. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954-5958, 2000
113. Pang JC, Chang Q, Chung YF, Teo JG, Poon WS, Zhou LF, et al: Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor. Hum Pathol 36:36-43, 2005 (Pubitemid 40215632)
114. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al: The genetic landscape of the childhood cancer medulloblastoma. Science 331:435-439, 2011
115. Peyre M, Commo F, Dantas-Barbosa C, Andreiuolo F, Puget S, Lacroix L, et al: Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. PLoS ONE 5:e12932, 2010
116. Pfister S, Hartmann C, Korshunov A: Histology and molecular pathology of pediatric brain tumors. J Child Neurol 24:1375-1386, 2009
117. Pfister S, Schlaeger C, Mendrzyk F, Wittmann A, Benner A, Kulozik A, et al: Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Res 35:e51, 2007
118. Pierson J, Hostager B, Fan R, Vibhakar R: Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol 90:1-7, 2008
119. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-442, 2002 (Pubitemid 34100955)
120. Prokhortchouk A, Hendrich B, Jørgensen H, Ruzov A, Wilm M, Georgiev G, et al: The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev 15:1613-1618, 2001 (Pubitemid 32702582)
121. Restrepo A, Smith CA, Agnihotri S, Shekarforoush M, Kongk ham PN, Seol HJ, et al: Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. Neuro Oncol 13:42-50, 2011
122. Roberts CW, Biegel JA: The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 8:412-416, 2009
123. Rousseau E, Ruchoux MM, Scaravilli F, Chapon F, Vinchon M, De Smet C, et al: CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol 29:574-583, 2003 (Pubitemid 37548352)
124. Ruiz i Altaba A, Palma V, Dahmane N: Hedgehog-Gli signalling and the growth of the brain. Nat Rev Neurosci 3:24-33, 2002
125. Rutka JT, Kongkham P, Northcott P, Carlotti C, Guduk M, Osawa H, et al: The evolution and application of techniques in molecular biology to human brain tumors: a 25 year perspective. J Neurooncol 92:261-273, 2009
126. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435-443, 2006 (Pubitemid 43832188)
127. Sanosaka T, Namihira M, Nakashima K: Epigenetic mechanisms in sequential differentiation of neural stem cells. Epigenetics 4:89-92, 2009
128. Scotting PJ, Walker DA, Perilongo G: Childhood solid tumours: a developmental disorder. Nat Rev Cancer 5:481-488, 2005 (Pubitemid 40791490)
129. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 31:27-36, 2010
130. Shi H, Wang MX, Caldwell CW: CpG islands: their potential as biomarkers for cancer. Expert Rev Mol Diagn 7:519-531, 2007 (Pubitemid 47547720)
131. Sredni ST, Bonaldo MdeF, Costa FF, Huang CC, Hamm CA, Rajaram V, et al: Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets. Childs Nerv Syst 26:279-283, 2010
132. Sterner DE, Berger SL: Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64:435-459, 2000 (Pubitemid 30412680)
133. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 403:41-45, 2000 (Pubitemid 30038513)
134. Su X, Gopalakrishnan V, Stearns D, Aldape K, Lang FF, Fuller G, et al: Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol 26:1666-1678, 2006
135. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, et al: Mutations in SUFU predispose to medulloblastoma. Nat Genet 31:306-310, 2002
136. Taylor MD, Mainprize TG, Rutka JT: Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 47:888-901, 2000 (Pubitemid 32103665)
137. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, et al: Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8:323-335, 2005 (Pubitemid 41443417)
138. Teider N, Scott DK, Neiss A, Weeraratne SD, Amani VM, Wang Y, et al: Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. Neuro Oncol 12:1244-1256, 2010
139. Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, et al: Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 23:1491-1499, 2005
140. Temple S: The development of neural stem cells. Nature 414:112-117, 2001
141. Tollefsbol T (ed): Handbook of Epigenetics: The New Mo lecular and Medical Genetics. San Diego, CA: Academic Press, 2011
142. Urdinguio RG, Sanchez-Mut JV, Esteller M: Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 8:1056-1072, 2009
143. Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A, et al: The miR-17-92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A 106:2812-2817, 2009
144. Venkataraman S, Alimova I, Fan R, Harris P, Foreman N, Vibhakar R: MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS ONE 5:e10748, 2010
145. Ventura A, Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell 136:586-591, 2009
146. Verdel A, Vavasseur A, Le Gorrec M, Touat-Todeschini L: Common themes in siRNA-mediated epigenetic silencing pathways. Int J Dev Biol 53:245-257, 2009
147. Vibhakar R, Foltz G, Yoon JG, Field L, Lee H, Ryu GY, et al: Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. Neuro Oncol 9:135-144, 2007 (Pubitemid 46580315)
148. Visvanathan J, Lee S, Lee B, Lee JW, Lee SK: The microRNA miR-124 antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS development. Genes Dev 21:744-749, 2007 (Pubitemid 46572354)
149. Wagner JM, Hackanson B, Lübbert M, Jung M: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 1:117-136, 2010
150. Waha A, Koch A, Hartmann W, Mack H, Schramm J, Sörensen N, et al: Analysis of HIC-1 methylation and transcription in human ependymomas. Int J Cancer 110:542-549, 2004 (Pubitemid 38658019)
151. Woodcock CL, Ghosh RP: Chromatin higher-order structure and dynamics. Cold Spring Harb Perspect Biol 2:a000596, 2010
152. Wu SC, Zhang Y: Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 11:607-620, 2010
153. Yang X, Lay F, Han H, Jones PA: Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 31:536-546, 2010
154. Zacharoulis S, Levy A, Chi SN, Gardner S, Rosenblum M, Miller DC, et al: Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 49:34-40, 2007 (Pubitemid 46847065)
155. Zacharoulis S, Moreno L: Ependymoma: an update. J Child Neurol 24:1431-1438, 2009
156. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17:832-845, 1999 (Pubitemid 29109313)
157. Zernicka-Goetz M, Morris SA, Bruce AW: Making a firm decision: multifaceted regulation of cell fate in the early mouse embryo. Nat Rev Genet 10:467-477, 2009
158. Zhao X, He X, Han X, Yu Y, Ye F, Chen Y, et al: MicroRNA-mediated control of oligodendrocyte differentiation. Neuron 65:612-626, 2010